Muneer Satter, a Director at Aileron Therapeutics, Inc., purchased $9,900,000 worth of stock and increasing his shares to 16,609,449.
|
COMPANY INFORMATION
|
||
|
ALRN by TradingView
|
Company Info:
Aileron is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.
|
LATEST INSIDER ACTIVITY
|
||
|
INSIDER:
Muneer A Satter
SHARES BOUGHT:
9,000,000
PURCHASE DATE:
1/08/2021 |
TITLE:
Director
% INCREASE:
118%
FILE DATE:
1/08/2021
|
|
|
INSIDER PURCHASE PRICE
N/A
|
||
Insider Notes:
N/A
|
ANALYST RECOMMENDATION
|
||
|
TARGET PRICE:
$3.50 TARGET GAIN:
300% |
AVERAGE RATING:
BUY ANALYST COVERING:
3 |
|
| IMPORTANT DISCLOSURE | ||
|
TECHNICAL ANALYSIS
|
||
|
|
|
|